 There is currently very limited information available on the incidence of venous thromboembolism VTE in patients undergoing lung cancer resection and the utility of extended thromboprophylaxis ET in this patient population. Furthermore, in contrast to patients undergoing orthopaedic surgery where ET has become standard of care, duration of thromboprophylaxis is not well defined in this patient population. Therefore, there is a clear need to systematically evaluate the effects of extended VTE prophylaxis on the incidence of VTE in the post-op population. 